NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rxsight-inc-lawsuit-submiss ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] Group 1: Company Overview - RxSight, Inc. specializes in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3] - The LAL can be customized post-surgery through non-invasive light treatments, utilizing a Light Delivery Device (LDD) to optimize vision based on individual patient needs [3] Group 2: Allegations and Market Impact - The lawsuit claims that RxSight failed to disclose "adoption challenges" in its products while promoting strong sales of LAL and LDD, despite experiencing a slowdown in LAL utilization first noted in 2024 [4] - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, citing a "softening" market that began in the second half of 2024, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5] - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell another 38%, from $12.79 to $7.95 per share [6]

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. for alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products [2]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2]. - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

Group 1 - A securities class action lawsuit has been filed against RxSight, Inc. on behalf of investors who purchased its securities [1] - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and it alleges securities fraud and unlawful business practices [6] - RxSight reported significant declines in sales of its Light Delivery Device and lower usage of light adjustable intraocular lenses, leading to an overall revenue shortfall [6] Group 2 - The company cut its full year 2025 guidance by approximately $42.5 million due to "adoption challenges" affecting sales [6] - Following the negative news, RxSight's stock price dropped by $4.84, a decrease of 37.84%, closing at $7.95 per share on July 9, 2025 [6] - The lead plaintiff deadline for the lawsuit is September 22, 2025, encouraging affected investors to contact the law firm for more information [6]

CLASS PERIOD: November 7, 2024 to July 8, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025 ...

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of RxSight, Inc. (NASDAQ: RXST). Shareholders who purchased shares of RXST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rxsight-inc-loss-submission-form/?id=158626&from=3 CLASS PERIOD: November 7, 2024 to ...

BENSALEM, Pa., July 30, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE SEPTEMBER 22, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howar ...

Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during a specified period [1][2]. Group 1: Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1] - The primary product of RxSight is the RxSight system, which includes the LAL and the Light Delivery Device (LDD) [1]. Group 2: Allegations and Financial Performance - The class action alleges that RxSight failed to disclose adoption challenges and structural issues leading to declines in sales and utilization of its products [2]. - The complaint claims that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, and lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, specifically related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell another 38% from $12.79 to $7.95 per share [6].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities between November 7, 2024, and July 8, 2025 [1][2] Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery [2] Legal Allegations - The lawsuit alleges that RxSight failed to disclose: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3] 2. Overstated demand for RxSight's products [3] 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3] Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance [4] - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4]